Treatment of colon cancer by EGFR inhibitors. Cetuximab (Erbitux). Panitumumab (Vectibix). 9

Examples of EGFR inhibitors are cetuximab (Erbitux) and panitumumab (Vectibix). They are most effective in patients with wild-type KRAS and NRAS colon cancer tumors. Anti-angiogenesis medications bevacizumab (Avastin) or Ranibizumab (Lucentis) are more difficult to use in colon cancer therapy.

Colon cancer treatment by cetuximab (Erbitux) and panitumumab (Vectibix). Targeted medications against EGFR pathway are monoclonal antibodies against the epidermal growth factor receptor. Leading German-American colorectal cancer oncologist discusses modern approach to use of EGFR pathway inhibitors in colon cancer treatment. EGFR inhibitors are active in KRAS and NRAS wild-type colon cancer tumors. Cetuximab (Erbitux) and panitumumab (Vectibix) lead to significant colon cancer tumor reduction in metastatic colon cancer. Tumor shrinkage can help to resect liver metastases in stage 4 colorectal cancer. Colorectal cancer EGFR pathway targeted chemotherapy options. Advanced stage 4 colon cancer treatment by targeted chemotherapy with Cetuximab (Erbitux) and panitumumab (Vectibix. Medical second opinion confirms colorectal cancer diagnosis at genetic level. Medical second opinion also confirms colon cancer cure is possible in metastatic colon cancer. Best precision medicine treatment for advanced stage 4 colon cancer with metastatic lesions. Medical second opinion helps to select a personalized medicine targeted treatment with EGFR inhibitors for stage 4 refractory colorectal cancer with liver or lung metastases. Get medical second opinion on advanced colorectal cancer. Be confident that your precision medicine treatment is the best. Best colorectal cancer treatment by new BRAF inhibitors, EGFR inhibitor monoclonal antibodies, anti-angiogenesis medications and multikinase inhibitors. Video interview with leading expert in metastatic colorectal cancer treatment from California. Colon cancer targeted treatment. Cetuximab (Erbitux) and panitumumab (Vectibix). Dr. Anton Titov, MD. Targeted therapy for colon cancer and rectal cancer is exemplified by cetuximab (Erbitux) and panitumumab (Vectibix). These targeted medications are monoclonal antibodies against the epidermal growth factor receptor, EGFR. EGFR inhibitors are usually added to conventional chemotherapy medications in colorectal cancer treatment. However, there are some contradictions in clinical trials on the use of molecular tumor markers in colon cancer. You must identify patients for whom EGFR inhibitors, cetuximab (Erbitux) and panitumumab (Vectibix) would work best. What is the current status of understanding of EGFR inhibitors? How can patients with colon cancer or rectal cancer benefit from EGFR inhibitors? Such as cetuximab (Erbitux) and panitumumab (Vectibix). Dr. Heinz-Josef Lenz, MD (Colorectal Cancer Expert, California). I think we have now a very good understanding when to use each of EGFR inhibitors in colon cancer therapy. Cetuximab (Erbitux) and panitumumab (Vectibix). Sometimes KRAS and NRAS is wild-type. Then we know that EGFR inhibitor in combination with classical chemotherapy will increase significantly the colon cancer tumor response rate. It will change up to 60% or 70%. There is no doubt about it. EGFR inhibitors also increase overall survival of patients with colon cancer. EGFR inhibitors, cetuximab (Erbitux) and panitumumab (Vectibix), also increase progression-free survival in colorectal cancer patients. I think the best results of EGFR inhibitor treatment in colon cancer is in the wild-type KRAS and NRAS colon cancer. EGFR inhibitors, cetuximab (Erbitux) and panitumumab (Vectibix) give us a significant increase of colon cancer tumor shrinkage. We know now how important tumor shrinkage might be for colorectal cancer patient with metastatic disease of the liver. Dr. Heinz-Josef Lenz, MD (Colorectal Cancer Expert, California). Because we can resect liver metastases surgically since the normal liver will grow back. That is very well understood. Now we do not have any validated molecular tumor markers for the antiangiogenic medications. We don’t know which colon cancer patient population benefits from antiangiogenic medications. We have no molecular tumor markers for bevacizumab (Avastin) or Ranibizumab (Lucentis). But for each EGFR inhibitors clearly we know what works well. Only colon cancer patients with wild-type KRAS and NRAS genes in their tumor benefit from the inhibition of EGFR molecular pathway. Colon cancer treatment by EGFR inhibitors. Cetuximab (Erbitux) and panitumumab (Vectibix) work best in wild-type KRAS and NRAS genes in colorectal cancer.